Thornton & Ross

Thornton & Ross is a well-established, revenue-generating pharmaceutical company and a major UK subsidiary of the STADA Group. It has demonstrated consistent year-on-year growth, reporting €267 million in sales for 2024, driven by a diversified portfolio spanning trusted consumer brands like Covonia and Savlon, a broad generics portfolio, and specialty medicines. The company leverages its long-standing UK commercial presence, manufacturing capabilities, and the international scale of its parent group to support a sustainable NHS and expand its market position in consumer healthcare and specialty therapeutic areas.

Integrated commercial and manufacturing infrastructure for generics, specialty pharmaceuticals, and consumer healthcare brands. Leverages parent company STADA's R&D platforms for complex generics and value-added medicines.

Operates in highly competitive segments: competes with global generics giants (Teva, Viatris) and consumer health conglomerates (Haleon, Reckitt) in the OTC space. Its specialty pharma business competes with both originator companies and other generic/specialty firms like Advanz Pharma or Accord Healthcare.